8-K

0001683168-24-001993.txt : 20240401 0001683168-24-001993.hdr.sgml : 20240401 20240401142622 ACCESSION NUMBER: 0001683168-24-001993 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240401 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41282 FILM NUMBER: 24808233 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 332-216-1147 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 8-K 1 sunshine_8k.htm CURRENT REPORT 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2024

SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Colorado

001-41282

20-5566275

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer ID No.)

1177 Avenue of the Americas, 5th Floor

New York , NY 10036

(Address of principal executive offices) (zip code)

(332) 216-1147

(Registrant’s telephone number, including area code)

________________________________________

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value $0.001	SBFM	The Nasdaq Stock Market LLC
Common Stock Purchase Warrants	SBFMW	The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On April 1, 2024, Sunshine Biopharma, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the period ended December 31, 2023. The press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release
104		Cover Page Interactive Data File (formatted in Inline XBRL).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 1, 2024	SUNSHINE BIOPHARMA, INC.


	By: /s/ Dr. Steve N. Slilaty
	Dr. Steve N. Slilaty, Chief Executive Officer

3

EX-99.1 2 sunshine_ex9901.htm PRESS RELEASE

Exhibit 99.1

SUNSHINE BIOPHARMA REPORTS OPERATING RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023

Sales Grew at an Average Rate of 14% Per Quarter During the Year

NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 financial results on Form 10-K on Thursday March 28, 2024. The following are highlights of the report:

·

Sales in 2023 grew to a total of $24,092,787, primarily as a result of a full year of revenues generated by the acquisition of Nora Pharma in October 2022. Nora Pharma’s revenues for its fiscal year ended June 30, 2022, were $10,766,982.

·

The average 2023 quarter-over-quarter growth rate in sales was 14%.

·

Loss per share decreased from a negative $1.76 per share in 2022 to a negative $0.19 per share in 2023, predominantly due to a one-time write-off of goodwill in 2022.

·

Completed a private placement of approximately $5 million in gross proceeds for use in part for expansion of sales operations.

·

Repurchased 513,723 shares of the Company’s common stock on the market for a total of $541,143.

·

The Company’s two proprietary drugs in development advanced to the animal testing stage for both SBFM-PL4 targeted for SARS Coronavirus infections and K1.1 mRNA for liver cancer.

·

IND-enabling studies of Adva-27a anticancer compound were halted in November 2023 pending further analysis of unfavorable in vitro results obtained earlier in the year.

“We are happy with our 2023 results, as we continue to strive to achieve profitability,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “We look forward to further growth in 2024 and beyond as we expand our operations and bring more life-saving drugs to market,” he added.

1

The following are key items contained in the Company’s Income Statement included in the 2023 10-K:

		2023				2022
Sales		$	24,092,787			$	4,345,603
Gross Profit		$	8,339,171			$	1,696,575
General & Administrative Expenses		$	13,124,470			$	28,697,325
Goodwill impairment		$	–			$	18,326,719
Net Loss		$	4,506,044			$	26,744,440

About Sunshine Biopharma Inc.

Sunshine Biopharma currently 52 generic prescription drugs on the market in Canada and 32 additional drugs scheduled to be launched in Canada in 2024 and 2025. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA for liver cancer, and (ii) PLpro protease inhibitor for SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

Safe Harbor Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

For Additional Information Contact:

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

2

EX-101.SCH 3 sbfm-20240401.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 sbfm-20240401_def.xml XBRL DEFINITION FILE EX-101.LAB 5 sbfm-20240401_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Common Stock Purchase Warrants [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 sbfm-20240401_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 image_001.gif GRAPHIC begin 644 image_001.gif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end XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 01, 2024
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 01, 2024
Entity File Number	001-41282
Entity Registrant Name	SUNSHINE BIOPHARMA, INC.
Entity Central Index Key	0001402328
Entity Tax Identification Number	20-5566275
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	1177 Avenue of the Americas,
Entity Address, Address Line Two	5th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10036
City Area Code	(332)
Local Phone Number	216-1147
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	SBFM
Security Exchange Name	NASDAQ
Common Stock Purchase Warrants [Member]
Title of 12(b) Security	Common Stock Purchase Warrants
Trading Symbol	SBFMW
Security Exchange Name	NASDAQ

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sunshinebiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sbfm-20240401.xsd sbfm-20240401_def.xml sbfm-20240401_lab.xml sbfm-20240401_pre.xml sunshine_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sunshine_8k.htm": { "nsprefix": "SBFM", "nsuri": "http://sunshinebiopharma.com/20240401", "dts": { "schema": { "local": [ "sbfm-20240401.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "sbfm-20240401_def.xml" ] }, "labelLink": { "local": [ "sbfm-20240401_lab.xml" ] }, "presentationLink": { "local": [ "sbfm-20240401_pre.xml" ] }, "inline": { "local": [ "sunshine_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://sunshinebiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "SBFM_CommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20240401", "localname": "CommonStockPurchaseWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrants [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001683168-24-001993-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-001993-xbrl.zip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end XML 19 sunshine_8k_htm.xml IDEA: XBRL DOCUMENT 0001402328 2024-04-01 2024-04-01 0001402328 us-gaap:CommonStockMember 2024-04-01 2024-04-01 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2024-04-01 2024-04-01 iso4217:USD shares iso4217:USD shares false 0001402328 8-K 2024-04-01 SUNSHINE BIOPHARMA, INC. CO 001-41282 20-5566275 1177 Avenue of the Americas, 5th Floor New York NY 10036 (332) 216-1147 Common Stock, par value $0.001 SBFM NASDAQ Common Stock Purchase Warrants SBFMW NASDAQ false false false false false